JCO at ASCO Annual Meeting: Neoadjuvant Osimertinib for Resectable EGFR-Mutated NSCLC

<p><em>JCO</em> Editorial Fellow Dr. Ece Cali Daylan and <em>JCO</em> Associate Editor Dr. Thomas Stinchcombe discuss the ASCO 2025 Simultaneous Publication paper "<a href= "https://ascopubs.org/doi/10.1200/JCO-25-00883" target="_blank" rel="noopener">Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer</a>."</p> <h2>Transcript</h2> <p class="MsoNormal" style="text-align: center;" align="center"> <span style="font-family: arial, helvetica, sans-serif;"><em style= "mso-bidi-font-style: normal;"><span lang="EN" xml:lang="EN">The guest on this podcast episode has no disclosures to declare.</span></em></span></p> <p class="MsoNormal" style="margin: 12.0pt 0in 12.0pt 0in;"> <span style= "font-family: arial, helvetica, sans-serif;"><strong style= "mso-bidi-font-weight: normal;"><span lang="EN" xml:lang="EN">Dr. Ece Cali:</span></strong> <span lang="EN" xml:lang="EN">Hello, and welcome to our 2025 ASCO Annual Meeting series, where we cover some of the top <em style="...